Vizz (aceclidine ophthalmic solution 1.44%) is a prescription eye drop FDA-approved on July 31, 2025, to treat presbyopia — the age-related near vision loss affecting roughly 128 million US adults. It’s the first and only aceclidine-based drop approved in the US, developed by LENZ Therapeutics.
Aceclidine contracts the iris sphincter muscle. The resulting pinhole effect sharpens near vision without requiring the lens to flex. Vizz works within 30 minutes and provides up to 10 hours of near vision improvement per dose. Three clinical studies covering 30,000+ use-days confirmed efficacy with no serious adverse events.
Vizz outperformed pilocarpine 1.25% (Vuity) in Phase 3 trials on near vision gains and uses a preservative-free, single-use vial format suitable for sensitive eyes. This review covers how it works, what users report, how it compares to competitors, and whether the monthly cost makes sense for your lifestyle.
What Are Vizz Eye Drops?
Vizz eye drops are a prescription aceclidine ophthalmic solution (1.44%) FDA-approved on July 31, 2025, to treat presbyopia — the age-related blurry near vision affecting approximately 128 million US adults. And yes, aceclidine is entirely new to the presbyopia category. No other approved drop uses it.
LENZ Therapeutics developed Vizz as the first and only aceclidine-based drop approved in the US. The product hit pharmacies starting October 2025, initially with samples flowing through prescribing eye doctors’ offices.
Here’s the target patient: any adult over 40 who’s constantly reaching for reading glasses to see phones, books, or menus. Vizz offers a once-daily, non-surgical alternative to corrective lenses for these everyday near vision headaches.
Vizz Key Facts:
| Feature | Detail |
|---|---|
| Active Ingredient | Aceclidine 1.44% |
| FDA Approval Date | July 31, 2025 |
| Availability | October 2025 (US pharmacies) |
| Dosing | Once daily, single-use vials |
| Preservative | Preservative-free |
| Prescription Required | Yes |
What Does Vizz Treat?
Presbyopia is the gradual stiffening of the eye’s natural lens with age. The process makes nearby focus progressively harder and typically begins in the mid-40s. The bad news? Nearly every adult experiences some degree of it by age 50.
Vizz is indicated specifically for age-related blurry near vision in adults. It doesn’t treat glaucoma, cataracts, or dry eye disease. Those are separate conditions entirely.
And the improvement is very practical. Users report clearer vision for reading books, checking labels, viewing smartphone screens, and scanning menus — the everyday tasks that reading glasses were previously handling.
Activities Improved by Vizz:
- Reading books and printed materials
- Viewing smartphone and tablet screens
- Scanning menus and product labels
- Working at a computer or laptop
- Reading fine print and medication instructions
How Does Vizz Work?
Aceclidine contracts the iris sphincter muscle, narrowing the pupil and creating a pinhole effect that extends depth of focus and sharpens near vision clarity. Here’s the key part: this physical mechanism doesn’t require the lens itself to flex.
Vizz is a predominantly pupil-selective miotic with minimal ciliary muscle stimulation. This selectivity is what sets it apart from pilocarpine, which acts on both the iris and ciliary body and is more likely to cause accommodation-related side effects.
Distance vision stays largely unaffected by the pinhole mechanism. That said, patients should use caution when night driving or working in dim light — the constricted pupil does reduce the amount of light entering the eye.
What Are the Benefits of Vizz Eye Drops?
Vizz provides up to 10 hours of improved near vision from a single daily application, freeing most users from reading glasses throughout the standard workday. The once-daily routine makes it easy to stick with, too.
The good news for sensitive-eye patients? The formula is preservative-free and comes in single-use vials. Each vial gets discarded after use — no contamination risk, no preservative buildup on the ocular surface.
And unlike LASIK monovision or corneal inlays, Vizz is fully reversible. Users who stop the drops return to their baseline presbyopia with no permanent changes to eye anatomy. That’s a significant upside for anyone still on the fence.
Key Benefits:
- Up to 10 hours of improved near vision per dose
- Onset within 30 minutes of application
- Preservative-free formula safe for sensitive eyes
- Fully reversible — no permanent eye changes
- Non-surgical alternative to monovision LASIK
Does Vizz Actually Improve Near Vision?
Yes. Vizz demonstrated statistically superior near vision improvement in GEMINI-1, the pivotal Phase 3 trial — a higher proportion of patients achieved ≥3 lines of near vision gain at 3 hours versus pilocarpine 1.25%. That trial was a central piece of the FDA submission package.
In fact, across three clinical studies totaling more than 30,000 days of combined use, Vizz produced measurable near vision improvement within 30 minutes in the majority of participants. The results were consistent and repeatable across the board.
Here’s what that means for patients: efficacy was consistent across age groups and baseline prescription levels. The drug doesn’t just work for some narrow slice of the presbyopia population — it works broadly.
How Long Do Vizz Effects Last?
A single daily dose of Vizz provides up to 10 hours of improved near vision, covering most daytime reading, screen use, and professional tasks for the majority of adults. That’s the longest studied duration of any currently approved presbyopia drop.
Improvement kicks in within 30 minutes of application. Morning use fits naturally into daily routines — full effect is present by the time most adults sit down to work or start their day.
The effect tapers after the 10-hour window. So what does that mean for evening readers? Users who need clear near vision after the effect wears off may still reach for reading glasses later in the night.
What Do Vizz Eye Drops Reviews Say?
Early Vizz user reports describe the drops as transformative — patients speak of reading phones, labels, and menus without glasses for the first time in years, with one user calling it ‘a paradigm shift.’ Overall early sentiment is strongly positive.
Celebrity users including Tiffani Thiessen, Shaun T, Rachel Nichols, and JoAnna Garcia Swisher have publicly shared positive experiences. Worth noting: these endorsements align well with the broad efficacy seen in clinical trials — they’re not completely detached from the data.
And here’s what real patients are actually saying: ‘I could read my phone without my glasses’ and ‘I am very, very pleased with the results’ — both from the official VIZZ testimonial page, both consistent with trial satisfaction data.
What Do Positive Vizz Reviews Report?
Positive Vizz reviewers consistently praise three things: the rapid 30-minute onset, the full-day duration, and the freedom to leave reading glasses at home during normal daytime activities. Speed and convenience dominate the praise.
Multiple reviewers highlight quality-of-life wins. Reading menus at restaurants, checking phone notifications during meetings, working at a computer without readers — social and professional situations come up again and again in positive reports.
Here’s the part most people care about: distance vision stays clear while near vision improves. Older presbyopia drops sometimes blurred far sight, which frustrated users. Vizz largely avoids that trade-off, per user reports.
What Complaints Do Vizz Users Mention?
Dim or dark vision is the most frequently cited complaint in user reviews, reported by approximately 16% of participants in clinical trials — most describe it as mild, temporary, and tolerable after a few days of use. It reflects the pupil constriction mechanism directly.
Around 13% of users reported headaches in clinical trials. Some reviewers describe a mild pressure sensation around the eyes shortly after application — this typically resolves within 30 to 60 minutes and doesn’t seem to drive discontinuation.
Night driving is a consistent advisory in user feedback. The constricted pupil reduces light intake, making low-light environments uncomfortable or visually unsafe. Bottom line: Vizz is a daytime drop, not an around-the-clock solution.
How Is Vizz Different From Other Presbyopia Drops?
Vizz is the first and only aceclidine-based presbyopia drop approved in the US — all competing options (Vuity and Qlosi) use pilocarpine, an older cholinergic agent with a different selectivity profile. That active ingredient distinction is the core differentiator.
Here’s why that matters: aceclidine is more pupil-selective than pilocarpine. Vizz acts predominantly on the iris sphincter with minimal ciliary muscle stimulation, reducing the risk of accommodative spasm — a well-documented complaint with pilocarpine-based drops.
GEMINI-1 trial data confirmed Vizz outperformed pilocarpine 1.25% in the proportion of patients achieving ≥3 lines of near vision gain at 3 hours. Head-to-head data versus Qlosi specifically is more limited but is expected in forthcoming ophthalmology literature.
How Does Vizz Compare to Vuity?
Vuity uses pilocarpine 1.25%, an older cholinergic agent, while Vizz uses aceclidine 1.44% — a newer, more pupil-selective molecule that causes less ciliary muscle stimulation. These aren’t tweaked versions of the same drug. They’re pharmacologically distinct.
GEMINI-1 data shows Vizz outperformed pilocarpine 1.25% in the proportion of patients achieving ≥3 lines of near vision improvement at 3 hours. By that specific efficacy measure, Vizz has the clinical edge.
Side effect profiles overlap — both cause pupil constriction effects like dim vision and redness. But Vizz’s pupil-selective action means a lower risk of ciliary spasm, which is a key differentiator that prescribers weigh when choosing between the two.
How Does Vizz Compare to Qlosi?
Qlosi uses pilocarpine 0.4%, a lower concentration than Vuity, for a gentler presbyopia effect — but it shares the same cholinergic mechanism as all pilocarpine-based drops. Vizz uses an entirely different active ingredient.
Both are once-daily prescription drops. Vizz has a studied duration of up to 10 hours — the longer-acting option for sustained daytime near vision improvement between the two.
Eye doctors choose between Vizz and Qlosi based on the individual patient — pilocarpine tolerance history, pupil size in dim light, lifestyle needs. A formal evaluation drives the decision, not a universal rule.
Presbyopia Drops Compared:
| Drop | Ingredient | Concentration | Duration |
|---|---|---|---|
| Vizz | Aceclidine | 1.44% | Up to 10 hours |
| Vuity | Pilocarpine | 1.25% | ~6 hours |
| Qlosi | Pilocarpine | 0.4% | ~6 hours |
What Are the Side Effects of Vizz Eye Drops?
Vizz carried no treatment-related serious adverse events across clinical trials spanning more than 30,000 days of use — the FDA describes the overall safety profile as generally well-tolerated. For a brand-new drug class, that’s a meaningful benchmark.
The four most common side effects are eye drop site irritation (20%), dim or dark vision (16%), headache (13%), and mild eye redness (8%). All described as mild. All resolved without intervention in most cases.
That said, LENZ Therapeutics advises patients to call an eye doctor immediately if flashing lights, new floaters, or sudden vision loss appear after using Vizz. These may signal retinal complications and need prompt evaluation — don’t wait on those symptoms.
Common Side Effects:
| Side Effect | Frequency | Severity |
|---|---|---|
| Eye drop site irritation | 20% | Mild |
| Dim or dark vision | 16% | Mild, temporary |
| Headache | 13% | Mild |
| Eye redness | 8% | Mild, resolves in 30 min |
What Are the Common Side Effects?
Eye drop site irritation is the most common side effect at 20% of users — it’s typically mild, lasts only minutes after application, and rarely causes patients to stop treatment. Most users get used to it within the first few days.
Dim or dark vision affects 16% of users and it’s a direct result of the pupil-constricting mechanism. The pupil admits less light when narrowed. That darkening effect resolves as the drop wears off over 10 hours — it’s not permanent.
Headache hit 13% of trial participants, and mild redness 8%. The redness typically resolved within 30 minutes of application in clinical trial data, suggesting a brief inflammatory response right at the drop site.
Who Should Avoid Vizz?
Patients with a known allergy to aceclidine or any Vizz ingredient should not use the drops — an allergy history review is a standard component of the formal VIZZ candidacy assessment. No exceptions are made for this contraindication.
Night drivers and workers in dim-light environments face a real practical concern with Vizz. Pupil constriction reduces available light, and that degrades vision quality in low-light conditions. Daytime-only users avoid this problem entirely.
The VIZZ evaluation process exists for exactly this reason. It checks pupil size, retinal health, and ocular surface health to rule out conditions that make the drops unsafe. Pre-prescription screening is the primary filter for unsuitable candidates.
Who Should Not Use Vizz:
- Patients allergic to aceclidine or any ingredient in the formula
- Adults who regularly drive at night or work in dim-light environments
- Patients with certain retinal conditions identified during a pre-use evaluation
- Those whose eye exam reveals a pupil size or anatomy not suitable for miotic therapy
Is Vizz FDA Approved and Legit?
Yes. Vizz received full US FDA approval on July 31, 2025. The drug is a regulated prescription medication subject to the same manufacturing, labeling, and post-market surveillance requirements as any other approved drug. It’s not a supplement. It’s not a gray-market product.
LENZ Therapeutics is a publicly traded clinical-stage company. The FDA approval was announced via an official press release on August 1, 2025. The approval is verifiable directly through the FDA drug database — look it up.
Three controlled clinical studies covering 30,000+ use-days were reviewed by the FDA before approval. No treatment-related serious adverse events were identified across the entire trial program. That’s the safety record the approval stands on.
What Clinical Studies Support Vizz?
GEMINI-1 was the pivotal Phase 3 clinical trial submitted to the FDA — it compared Vizz directly to pilocarpine 1.25% and a vehicle control, measuring near vision gains at multiple time points from 30 minutes through 10 hours post-dose. Vizz outperformed both comparators on primary endpoints.
In total, three clinical studies contributed 30,000+ days of safety and efficacy data to the FDA submission. Patient populations spanned diverse age ranges and baseline prescriptions, which is why the labeling covers all adults with presbyopia broadly.
And the scientific rationale holds up: ophthalmology literature has described aceclidine’s mechanism as pharmacologically distinct from pilocarpine, with higher pupil selectivity and a more favorable accommodative side-effect profile. The clinical results have a solid mechanistic basis.
How Much Does Vizz Cost?
Vizz is a prescription-only branded medication; comparable presbyopia drops like Vuity have retailed at approximately $80-$90 (USD) per month without insurance — Vizz is expected to be in a similar price range at launch. Exact pricing varies by pharmacy.
The good news? LENZ Therapeutics offers a VIZZ Savings Card for eligible commercially insured patients. It significantly reduces out-of-pocket costs and is accessible through the prescribing doctor’s office or the official LENZ website.
Reading glasses cost $10-$50 (USD) as a one-time purchase. Vizz is a recurring monthly expense. The value calculation depends entirely on how heavily a patient relies on near vision throughout the day — casual readers and power users are in very different situations.
Is Vizz Covered by Insurance?
No. Insurance coverage for Vizz is not yet standardized — as a newly approved brand-name drug launched in October 2025, many insurance formularies had not yet added Vizz as a covered medication in the initial rollout period. Coverage is expected to expand as market traction grows.
In the meantime, the VIZZ Savings Card is accessible through lenztherapeutics.com or via the prescribing doctor’s office. Commercially insured patients without formulary coverage can use the card to reduce costs immediately.
Worth knowing: many insurers require prior authorization before covering branded presbyopia drops. Plans may also require proof that less expensive options like reading glasses were tried first. That prior auth step adds some friction to access.
Is Vizz Worth the Price?
Yes — for most active presbyopia patients. Vizz delivers 10 hours of glasses-free reading and screen time, a tangible productivity benefit that heavy readers, writers, and screen workers consistently describe as high-value. The return on investment is lifestyle-dependent.
Clinical participants and real-world users consistently put quality of life at the center of the value story. Freedom from reading glasses in meetings, restaurants, and social settings is what patients actually value — the 10-hour window is what makes that possible.
That said, casual readers and those with mild presbyopia who only occasionally need readers may find the monthly cost hard to justify. A $15 (USD) pair of OTC readers handles the same intermittent need at a fraction of the ongoing cost.
Where Can You Buy Vizz Eye Drops?
Vizz is a prescription-only medication dispensed at retail and specialty pharmacies across the US — it can’t be purchased over the counter or online without a valid prescription from a licensed eye care provider. An eye exam is the required first step, no way around it.
The access pathway has three steps: a comprehensive eye exam, a Vizz evaluation to confirm candidacy, and a written prescription filled at any participating pharmacy. Most major chains stock Vizz or can order it within one to two business days.
LENZ Therapeutics confirmed samples and initial product availability starting October 2025, with broader national pharmacy distribution by end of 2025. Patients in rural areas should confirm availability with their local pharmacy before booking an evaluation.
How to Get Vizz:
- Schedule a comprehensive eye exam with a licensed optometrist or ophthalmologist.
- Ask your doctor about a formal VIZZ evaluation to confirm candidacy.
- Receive a written prescription if you are a suitable candidate.
- Fill the prescription at a participating retail or specialty pharmacy.
- Apply the VIZZ Savings Card at checkout if paying out of pocket.
Can You Use Vizz With Contact Lenses?
Yes. Contact lens wearers can use Vizz, but standard guidance requires removing soft lenses before applying the drop and waiting at least 10 to 15 minutes before reinserting them. This timing prevents the lens material from absorbing the active ingredient before it reaches the eye properly.
A VIZZ evaluation for contact lens wearers includes an ocular surface health check and lens fit assessment. The goal is ensuring Vizz doesn’t interact adversely with the lens type or the underlying corneal surface before prescribing.
Patients who’ve had LASIK or cataract surgery can also be evaluated for Vizz if residual presbyopia persists. Eye doctors assess candidacy case by case — surgical history and current refraction both factor into the prescribing decision.
Should You Try Vizz Eye Drops?
Yes, if you’re an active adult over 40 with confirmed presbyopia. Vizz is best suited for those who want 10 hours of glasses-free near vision daily and regularly rely on their eyes for reading, screens, or fine detail work. Active readers and professionals get the most out of it.
Adults with very advanced presbyopia may still need glasses for fine print even with Vizz. And those in dim-light professions face reduced utility — the pupil-constriction effect limits light intake in low-light environments, which can be a real problem for some users.
Bottom line: with full FDA approval, strong Phase 3 clinical trial data, a first-in-class mechanism, and broadly positive early user reviews, Vizz is a legitimate and well-evidenced option for managing presbyopia without glasses. It’s worth a conversation with an eye care provider.